Shogo Kamikawaji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shogo Kamikawaji has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Akihisa Sakamoto
Research Division, Chugai Pharmaceutical, Yokohama, Kanagawa, Japan
34 shared publications - Chai Ling Pang
Research Division, Chugai Pharmabody Research, Singapore, Singapore
34 shared publications - Chiew Ying Yeo
Research Division, Chugai Pharmabody Research, Singapore, Singapore
34 shared publications - Futa Mimoto
Research Division, Chugai Pharmabody Research, Singapore, Singapore
34 shared publications - Haruka Kuroi
Discovery Biologics Department, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan
34 shared publications - Hiroaki Nagano
Research Division, Chugai Pharmabody Research, Singapore, Singapore
34 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Epitope-diverse autoantibodies induce neutrophil–epithelial niches driving kidney injury in ANCA-associated glomerulonephritis
Autoantibody-mediated inflammation drives tissue injury in autoimmune diseases, yet how pathogenic antibodies evoke local immune activation remains poorly understood. Here, we show that spatially organized neutrophil–epithelial niches contribute to kidney injury in myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody–associated glomerulonephritis. Single-cell–resolved spatial transcriptomics of treatment-naïve patient kidney biopsies identified early-phase inflammatory niches enriched with HAVCR1+ injured proximal tubular epithelial cells, neutrophils, lymphocytes, and TREM2+ macrophages. Injured epithelial cells expressed chemokines including CXCL6 and CXCL16, defining a microenvironment associated with local immune cell accumulation. Neutrophils within these niches were characterized by transcriptional programs enriched for type II interferon and Fcγ receptor (FcγR)-related signaling. Mechanistically, combinations of monoclonal anti-MPO antibodies recognizing distinct epitopes enhanced neutrophil activation and induced pauci-immune crescentic glomerulonephritis in mice, recapitulating key aspects of epithelial injury observed in human kidneys. One-armed anti-MPO antibodies engineered to minimize FcγR engagement ameliorated kidney injury in mice. Together, these findings identify pathogenic neutrophil–epithelial niche formation as a driver of autoimmune kidney injury.
- 19 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Open AccessEpitope-diverse autoantibodies induce neutrophil–epithelial niches driving kidney injury in ANCA-associated glomerulonephritis
Autoantibody-mediated inflammation drives tissue injury in autoimmune diseases, yet how pathogenic antibodies evoke local immune activation remains poorly understood. Here, we show that spatially organized neutrophil–epithelial niches contribute to kidney injury in myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody–associated glomerulonephritis. Single-cell–resolved spatial transcriptomics of treatment-naïve patient kidney biopsies identified early-phase inflammatory niches enriched with HAVCR1+ injured proximal tubular epithelial cells, neutrophils, lymphocytes, and TREM2+ macrophages. Injured epithelial cells expressed chemokines including CXCL6 and CXCL16, defining a microenvironment associated with local immune cell accumulation. Neutrophils within these niches were characterized by transcriptional programs enriched for type II interferon and Fcγ receptor (FcγR)-related signaling. Mechanistically, combinations of monoclonal anti-MPO antibodies recognizing distinct epitopes enhanced neutrophil activation and induced pauci-immune crescentic glomerulonephritis in mice, recapitulating key aspects of epithelial injury observed in human kidneys. One-armed anti-MPO antibodies engineered to minimize FcγR engagement ameliorated kidney injury in mice. Together, these findings identify pathogenic neutrophil–epithelial niche formation as a driver of autoimmune kidney injury.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S6. Cross-reactivity of DLL3 trispecific.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S6. Cross-reactivity of DLL3 trispecific.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S2. Overview of the generation of the CD3/CD137 dual-specific Fab
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S2. Overview of the generation of the CD3/CD137 dual-specific Fab
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S7. DLL3 expression of SCLC xenograft models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S7. DLL3 expression of SCLC xenograft models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S4. DLL3 trispecific induces multiple cytokine production and DLL3- dependent cytotoxicity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S4. DLL3 trispecific induces multiple cytokine production and DLL3- dependent cytotoxicity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S8. DLL3 trispecific induced activation of tumor-infiltrating T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S8. DLL3 trispecific induced activation of tumor-infiltrating T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S5. DLL3 trispecific induces cytotoxicity against non-SCLC tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S5. DLL3 trispecific induces cytotoxicity against non-SCLC tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Pharmacokinetic parameters of DLL3 trispecific in cynomolgus monkeys
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Pharmacokinetic parameters of DLL3 trispecific in cynomolgus monkeys
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S9. The use of dexamethasone and tocilizumab does not limit the antitumor efficacy of DLL3 trispecific.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S9. The use of dexamethasone and tocilizumab does not limit the antitumor efficacy of DLL3 trispecific.